Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03328507 · ClinicalTrials.gov registry record · Phase 2

A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects

A Phase 2 study, sponsored by Braintree Laboratories.

Completed
Registry status
Phase 2
Development phase
121
Enrollment target

NCT03328507 is a Phase 2 study that has completed, run by Braintree Laboratories. The registered enrollment target is 121 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03328507, a Phase 2 study, has completed, sponsored by Braintree Laboratories.

COMPLETED
Registry status
Phase 2
Development phase
121 participants
Enrollment target

Study Summary

The objective of this study is to evaluate the safety and efficacy of BLI4900 as a bowel preparation prior to colonoscopy in adult patients.

Interventions

  • DRUG BLI4900
  • DRUG PEG Control

Trial Details

FieldValue
Enrollment Target 121 participants
Start Date 2017-11-09
Est. Completion 2019-11-12
Phase Phase 2

Sponsor

Braintree Laboratories

49 total trials

What the Registry Record Tells You About NCT03328507

The ClinicalTrials.gov registry entry for NCT03328507 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Braintree Laboratories, which has 49 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which BLI4900 is the first listed.

NCT03328507 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03328507 about?

NCT03328507 is a clinical study titled "A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects". The objective of this study is to evaluate the safety and efficacy of BLI4900 as a bowel preparation prior to colonoscopy in adult patients.

What is the current status of trial NCT03328507?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2017-11-09. Estimated completion is 2019-11-12.

What interventions are being tested in trial NCT03328507?

The interventions under investigation include: BLI4900 (DRUG), PEG Control (DRUG).

Who is sponsoring clinical trial NCT03328507?

This trial is sponsored by Braintree Laboratories, which has 49 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.